Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating
On February 17, 2026, Jefferies analyst Roger Song raised the price target on Krystal Biotech, Inc. (NASDAQ:KRYS) to $371 from $310 and maintained a Buy rating.






